alendronate and tamoxifen

alendronate has been researched along with tamoxifen in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (11.11)	18.2507
2000's	5 (55.56)	29.6817
2010's	3 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE	1
Mincey, BA; Moraghan, TJ; Perez, EA	1
Moore, HC	1
Grady, D	1
Brown, IN; Cohen, A; Fleischer, JB; Hershman, DL; Joe, AK; Johnson, MK; McMahon, DJ; Silverberg, SJ	1

Reviews

2 review(s) available for alendronate and tamoxifen

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic proceedings, 2000, Volume: 75, Issue:8 Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2000

Trials

1 trial(s) available for alendronate and tamoxifen

Article	Year
Prevention of bone loss after withdrawal of tamoxifen. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2008, Volume: 14, Issue:2 Topics: Absorptiometry, Photon; Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Serum Albumin; Substance Withdrawal Syndrome; Tamoxifen; Treatment Outcome	2008

Article

Year

Prevention of bone loss after withdrawal of tamoxifen.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2008, Volume: 14, Issue:2

Topics: Absorptiometry, Photon; Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Serum Albumin; Substance Withdrawal Syndrome; Tamoxifen; Treatment Outcome

2008

Other Studies

6 other study(ies) available for alendronate and tamoxifen

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone, 1996, Volume: 18, Issue:6 Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus	1996
Managing menopause after breast cancer: balancing risks and benefits. Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:3 Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors	2001
A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA, 2002, Apr-24, Volume: 287, Issue:16 Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrocystic Breast Disease; Hot Flashes; Humans; Hysterectomy; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	2002